|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.91 USD | +0.34% |
|
-2.07% | -13.88% |
| Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
| Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
CRISPR Therapeutics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 371.21 million compared to USD 1.2 million a year ago. Net loss was USD 153.61 million compared to USD 650.18 million a year ago.
Basic loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago. Diluted loss per share from continuing operations was USD 1.94 compared to USD 8.36 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.88% | 4.58B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CRISPR THERAPEUTICS AG 
